B.A. Schrock Wealth Management Inc. Makes New $1.61 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

B.A. Schrock Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, Holdings Channel reports. The fund acquired 2,188 shares of the biopharmaceutical company’s stock, valued at approximately $1,608,000.

A number of other hedge funds have also modified their holdings of the company. Arjuna Capital boosted its holdings in Regeneron Pharmaceuticals by 3.2% during the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 14 shares during the last quarter. Boyd Watterson Asset Management LLC OH boosted its stake in shares of Regeneron Pharmaceuticals by 1.4% during the 1st quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 15 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after acquiring an additional 15 shares in the last quarter. Aaron Wealth Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the 1st quarter. Aaron Wealth Advisors LLC now owns 1,102 shares of the biopharmaceutical company’s stock valued at $851,000 after acquiring an additional 16 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 16 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,946 shares of company stock worth $3,302,458 over the last three months. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $778.36 on Thursday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $564.00 and a 12 month high of $859.34. The firm has a market cap of $80.14 billion, a P/E ratio of 19.24, a P/E/G ratio of 1.30 and a beta of 0.16. The company’s 50-day moving average price is $791.11 and its two-hundred day moving average price is $720.89.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the prior year, the firm posted $12.81 EPS. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. HSBC lifted their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Truist Financial boosted their price objective on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a research report on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $834.24.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.